The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-11-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Collect the details about hepatic dysfunctional patients induced by various etiology who have a usage of Glycyrrhizic Acid, then arrange and analyse the data to evaluate the clinical curative effect of glycyrrhizic acid.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This experiment will screen and collect qualified cases from medical records in Shuguang Hospital.to collect the patients with liver injury in clinic, including (1) conforms to ALT\>1.5 times the normal value or \>70 IU/L, age 18 to 70 years of age, sex is not limited; (2) patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; (3) except for tumor patients. The index of liver function such as ALT, AST, Alb, et al are detected respectively before and after preventive treatment of the glycyrrhizic acid for liver injury ,and through the synthesizing of the single sample difference t test and clinical practice to analyze the clinical efficacy of glycyrrhizin intervention treatment of hepatic injury

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Damage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. conforms to ALT\>1.5 times the normal value or \>70IU/L, age 18 to 70 years of age, sex is not limited;
2. patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ;

Exclusion Criteria

1. patients with tumor;
2. pregnant or lactating women, and pregnancy may not take effective contraceptive measures;
3. complicated with serious heart, lung, gallbladder, kidney, endocrine, hematopoietic system and mental disease;
4. the researchers think that should not be selected for this test.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chao Wu

postgraduate

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shuguang Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wu Chao, postgraduate

Role: CONTACT

Phone: 15221095202

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sun Mingyu, professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-365-61-01

Identifier Type: -

Identifier Source: org_study_id